Search Results - "Port, Elisa R."

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance) by Sikov, William M, Berry, Donald A, Perou, Charles M, Singh, Baljit, Cirrincione, Constance T, Tolaney, Sara M, Kuzma, Charles S, Pluard, Timothy J, Somlo, George, Port, Elisa R, Golshan, Mehra, Bellon, Jennifer R, Collyar, Deborah, Hahn, Olwen M, Carey, Lisa A, Hudis, Clifford A, Winer, Eric P

“…One third of patients with triple-negative breast cancer (TNBC) achieve pathologic complete response (pCR) with standard neoadjuvant chemotherapy (NACT). CALGB…”
Get full text

PRKCQ inhibition enhances chemosensitivity of triple-negative breast cancer by regulating Bim by Byerly, Jessica H, Port, Elisa R, Irie, Hanna Y

“…Abstract Background Protein kinase C theta, (PRKCQ/PKCθ) is a serine/threonine kinase that is highly expressed in a subset of triple-negative breast cancers…”
Get full text

Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease by Sato, Katsutoshi, Padgaonkar, Amol A., Baker, Stacey J., Cosenza, Stephen C., Rechkoblit, Olga, Subbaiah, D. R. C. Venkata, Domingo-Domenech, Josep, Bartkowski, Alison, Port, Elisa R., Aggarwal, Aneel K., Ramana Reddy, M. V., Irie, Hanna Y., Reddy, E. Premkumar

“…Triple negative breast cancer (TNBC) remains challenging because of heterogeneous responses to chemotherapy. Incomplete response is associated with a greater…”
Get full text

VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche by MacDonald, Daniel D, Jensen, Kristian K, Kerns, Scott A, Lyden, David, Zhu, Zhenping, Wu, Yan, Riba, Rebecca D, Shido, Koji, Rafii, Shahin, Kaplan, Rosandra N, Port, Elisa R, Jin, David K, Ruggero, Davide, Hicklin, Daniel, Port, Jeffrey L, Vincent, Loïc, Altorki, Nasser, Costa, Carla, Shmelkov, Sergey V, Bramley, Anna H, Zacharoulis, Stergios

“…The cellular and molecular mechanisms by which a tumour cell undergoes metastasis to a predetermined location are largely unknown. Here we demonstrate that…”
Get full text

HER-2/neu status is a determinant of mammary aromatase activity in vivo : Evidence for a cyclooxygenase-2-dependent mechanism by SUBBARAMAIAH, Kotha, HOWE, Louise R, PORT, Elisa R, BROGI, Edi, FISHMAN, Jack, LIU, Catherine H, HLA, Timothy, HUDIS, Clifford, DANNENBERG, Andrew J

“…Cytochrome P450 aromatase (aromatase), a product of the CYP19 gene, catalyzes the synthesis of estrogens from androgens. Given the significance of estrogen…”
Get full text

Reoperative Sentinel Lymph Node Biopsy after Previous Mastectomy by Karam, Amer, MD, Stempel, Michelle, BS, Cody, Hiram S., MD, FACS, Port, Elisa R., MD, FACS

“…Background Sentinel lymph node (SLN) biopsy is the standard of care for axillary staging in breast cancer, but many clinical scenarios questioning the validity…”
Get full text

Lymphedema Precautions: Time to Abandon Old Practices? by Ahn, Soojin, Port, Elisa R

“…The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a…”
Get full text

Priming the 'soil' for breast cancer metastasis: the pre-metastatic niche by Psaila, Bethan, Kaplan, Rosandra N, Port, Elisa R, Lyden, David

“…The long prevailing model of metastasis recognizes the importance of both "seed" and "soil" for metastatic progression [1]. Much attention has focused on…”
Get more information

Surgery No More? Managing the Primary Tumor in Stage IV Breast Cancer by Anderson, David N, Port, Elisa R

“…The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a…”
Get full text

Genetic Testing in Patients With Newly Diagnosed Breast Cancer: Room for Improvement by Ahn, Soojin, Port, Elisa R

Get full text

CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer by Shepherd, Jonathan H, Ballman, Karla, Polley, Mei-Yin C, Campbell, Jordan D, Fan, Cheng, Selitsky, Sara, Fernandez-Martinez, Aranzazu, Parker, Joel S, Hoadley, Katherine A, Hu, Zhiyuan, Li, Yan, Soloway, Matthew G, Spears, Patricia A, Singh, Baljit, Tolaney, Sara M, Somlo, George, Port, Elisa R, Ma, Cynthia, Kuzma, Charles, Mamounas, Eleftherios, Golshan, Mehra, Bellon, Jennifer R, Collyar, Deborah, Hahn, Olwen M, Hudis, Clifford A, Winer, Eric P, Partridge, Ann, Hyslop, Terry, Carey, Lisa A, Perou, Charles M, Sikov, William M

“…CALGB 40603 (NCT00861705), a 2 × 2 randomized phase II trial, demonstrated that adding carboplatin or bevacizumab to weekly paclitaxel (wP) followed by…”
Get full text

Reply to A. Gomberawalla et al and J. Nudelman by Ahn, Soojin, Port, Elisa R

Get full text

Decision-Making in Breast Cancer Surgery: Where Do Patients Go for Information? by Schmidt, Hank, Cohen, Almog, Mandeli, John, Weltz, Christina, Port, Elisa R

“…Patient decision-making regarding breast cancer surgery is multifactorial, and patients derive information on surgical treatment options from a variety of…”
Get more information

Close and Positive Lumpectomy Margins are Associated with Similar Rates of Residual Disease with Additional Surgery by Fitzgerald, Simon, Romanoff, Anya, Cohen, Almog, Schmidt, Hank, Weltz, Christina, Bleiweis, Ira J., Jaffer, Shabnam, Port, Elisa R.

“…Background Current guidelines state that “no ink on tumor” constitutes adequate surgical margins for lumpectomy specimens. However, there remains uncertainty…”
Get full text

Breast Pathology Review: Does It Make a Difference? by Romanoff, Anya M., Cohen, Almog, Schmidt, Hank, Weltz, Christina R., Jaffer, Shabnam M., Nagi, Chandandeep S., Bleiweiss, Ira J., Port, Elisa R.

“…Background Breast pathology is a challenging field, and previous work has shown discrepancies in diagnoses, even among experts. We set out to determine whether…”
Get full text

Clinicopathologic predictors of MRI utilization in newly diagnosed breast cancer patients by Romanoff, Anya M., MD, McMurray, Matthew, Tabrizian, Parissa, MD, Weltz, Christina, MD, FACS, Friedman, Kathryn, Schwartzman, Monica, Margolies, Laurie, MD, FACR, Port, Elisa R., MD, FACS, Schmidt, Hank, MD, PhD, FACS

Get full text

Does the Benefit of Sentinel Node Frozen Section Vary Between Patients With Invasive Duct, Invasive Lobular, and Favorable Histologic Subtypes of Breast Cancer? by CHAN, Sharon Wing-Wai, LAVIGNE, Katherine A, PORT, Elisa R, FEY, Jane V, BROGI, Edi, BORGEN, Patrick I, CODY, Hiram S

“…Although many questions regarding sentinel lymph node (SLN) biopsy in breast cancer have been answered by observational studies and, increasingly, by…”
Get full text

Predictors of Completion Axillary Lymph Node Dissection in Patients with Positive Sentinel Lymph Nodes by Karam, Amer K., Hsu, Meier, Patil, Sujata, Stempel, Michelle, Traina, Tiffany A., Ho, Alice Y., Cody, Hiram S., Port, Elisa R., Morrow, Monica, Gemignani, Mary L.

“…Background Completion axillary lymph node dissection (CALND) is routinely performed in breast cancer patients with positive sentinel lymph nodes (SLN). We…”
Get full text

From the Guest Editors by Disa, Joseph J., Port, Elisa R.

Get full text

Kaplan et al. reply by Zacharoulis, Stergios, Wels, J, Bramley, Anna H, Kaplan, Rosandra N, Riba, Rebecca D, Kerns, Scott A, Hicklin, Daniel, Shmelkov, Sergey V, Jensen, Kristian K, Lyden, David, Port, Elisa R, Costa, Carla, Jin, David K, Port, Jeffrey L, Rafii, Shahin, MacDonald, Daniel D, Wu, Yan, Ruggero, Davide, Zhu, Zhenping, Altorki, Nasser, Vincent, Loïc, Shido, Koji

“…Replying to: M. R. Dawson et al. Nature 461, 10.1038/nature08254 (2009)Commenting on ref. 1, Dawson et al. claim that metastasis formation is independent of…”
Get full text